MyLungCancerTeam

KRAS mutations are found in 20-30% of lung cancer cases, particularly in non-small cell lung cancer (NSCLC). While each person's experience with KRAS-mutated lung cancer is unique, there have been significant treatment advances in recent years that have improved outcomes for many patients.

The FDA has approved two targeted Show Full Answer

KRAS mutations are found in 20-30% of lung cancer cases, particularly in non-small cell lung cancer (NSCLC). While each person's experience with KRAS-mutated lung cancer is unique, there have been significant treatment advances in recent years that have improved outcomes for many patients.

The FDA has approved two targeted therapies specifically for KRAS mutations - sotorasib (Lumakras) and adagrasib (Krazati). These medications were a breakthrough since KRAS mutations were previously considered untreatable with targeted therapies. For patients with the specific KRAS G12C mutation, these targeted treatments can be used after trying at least one other therapy. While it's not possible to guarantee that cancer won't recur, working closely with your healthcare team to monitor your condition and following your prescribed treatment plan gives you the best chance for positive outcomes.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

6 Lung Cancer Mutations and Treatments That Target Them

LUNGevity Launches First of Six Resource Portals for Specific Types of Lung Cancer